Barclays reinstates its coverage of Jazz Pharmaceuticals ( JAZZ ) with an Overweight rating and $200 price target. The target represents a 32% premium over today's price. Post your comment!
Jazz Pharmaceuticals , Inc. ( JAZZ ) Q4 2013 Earnings Conference Call February 25 ..... Tanner - FBR Capital Markets Presentation Operator Welcome to the Jazz Pharmaceuticals ' Fourth Quarter and Year End 2013 Earnings Conference Call. Following
Complete Story »
This morning I came across one of the most amazing stock charts that I have ever seen. My brother recommended Jazz pharmaceuticals plc ( JAZZ ) to me back in 2009, while we were day trading our private accounts. At the time, the stock was
collaborations with Celgene ( CELG ) $65 billion market cap; Avanir ( AVNR ), $546 million market cap; and Jazz Pharmaceuticals ( JAZZ ) $8.3 billion market cap. An earlier collaboration with GlaxoSmithKline ( GSK ), $130 billion market
By Shawn Arshad : Jazz Pharmaceuticals PLC ( JAZZ ), a mid-cap Pharma equity based in Ireland has been a very successful trade on NASDAQ since 2007. The company specializes
Associates (JKHY): Q3 EPS of $0.38 in-line. Revenue of $240M (+12% Y/Y) misses by $2M . ( PR ) Jazz Pharmaceuticals (JAZZ): Q1 EPS of $0.59 beats by $0.02 . Revenue of $51M (+45% Y/Y) in-line. Shares -0.38
Application to the FDA for the injection formula of FUSILEV, used to treat colorectal cancer (Jan. 2011). 4. Jazz Pharmaceuticals , Inc. (JAZZ): Market cap of $920.46M. Moving Averages: The stock is currently 4.28% above its 20